AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16760409 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient CCL3 production phenotype
Number of subjects: 0
Study 14735686 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (weekly)
Number of subjects: 0
Study 14735686 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (twice weekly for 2 weeks repeated every 21 days)
Number of subjects: 0
Study 14735686 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule C (twice weekly every other week)
Number of subjects: 0
Study 10872013 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary sanction intervention group (n=1500)
Number of subjects: 2500
Study 10872013 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=1000)
Number of subjects: 2500
Study 9123739 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant total androgen deprivation using LHRH analog (goserelin) plus flutamide for 3 months
Number of subjects: 354
Study 9123739 — intervention group
Group type: COMPARATOR
Intervention: Direct radical prostatectomy
Number of subjects: 354
Study 7901080 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboprost trometamol
Number of subjects: 150
Study 7901080 — intervention group
Group type: COMPARATOR
Intervention: Methylergometrine
Number of subjects: 150
Study 4025164 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP (250 mg/kg body weight in isotonic saline solution intravenously in 20 minutes)
Number of subjects: 40
Study 4025164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30954336 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry exposure (n = 44)
Number of subjects: 84
Study 30954336 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 84
Study 30954336 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry exposure
Number of subjects: 84
Study 30108392 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10mg orally via nasogastric tube at admission
Number of subjects: 80
Study 30108392 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 80
Study 26086689 — intervention group
Group type: EXPERIMENTAL
Intervention: Active awareness on physical health
Number of subjects: 0
Study 26086689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 0
Study 23721512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine-based combinations (CMC: 2-CdA, cyclophosphamide, mitoxantrone; CC: 2-CdA, cyclophosphamide)
Number of subjects: 0
Study 23721512 — intervention group
Group type: COMPARATOR
Intervention: 2-CdA monotherapy
Number of subjects: 0
Study 23721512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine-based combinations (CMC, CC)
Number of subjects: 0
Study 21855284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tpos1-adequate group
Number of subjects: 48
Study 21855284 — intervention group
Group type: COMPARATOR
Intervention: Tpos1-inadequate group
Number of subjects: 48
Study 21855284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tpos1
Number of subjects: 48
Study 20584260 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP 2 pmol kg(‐1) min(‐1)
Number of subjects: 17
Study 20584260 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP 5 pmol kg(‐1) min(‐1)
Number of subjects: 17
Study 20584260 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 0.75 pmol kg(‐1) min(‐1)
Number of subjects: 17
Study 20584260 — intervention group
Group type: COMPARATOR
Intervention: NaCl (Control)
Number of subjects: 17
Study 17354241 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing
Number of subjects: 2193
Study 17354241 — intervention group
Group type: COMPARATOR
Intervention: Cytology testing
Number of subjects: 2193
Study 17354241 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV-positive smear
Number of subjects: 2193
Study 15716285 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 352
Study 15716285 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II blockade (losartan)
Number of subjects: 352
Study 15716285 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 352
Study 15716285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic heart failure
Number of subjects: 352
Study 12045171 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg daily) for 28 days
Number of subjects: 40
Study 12045171 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 9468739 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image measures for females (NBS-Female, CBS, ABS, LTB)
Number of subjects: 172
Study 9468739 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image measures for males (NBS-Male, CBS, ABS, LTB)
Number of subjects: 172
Study 9468739 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese and very obese females
Number of subjects: 172
Study 7710412 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo device, chewed for four minutes, twice daily
Number of subjects: 30
Study 7710412 — intervention group
Group type: COMPARATOR
Intervention: Control group (customary oral hygiene procedures only)
Number of subjects: 30
Study 7710412 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo device
Number of subjects: 30
Study 2632755 — intervention group
Group type: COMPARATOR
Intervention: Dialysis with a 'low-calcium' dialysate (1.50 mmol/l)
Number of subjects: 26
Study 2632755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis with a 'high-calcium' dialysate (1.75 mmol/l)
Number of subjects: 26
Study 29124329 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, home-based program (Onco-Move)
Number of subjects: 63
Study 29124329 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity, combined supervised resistance and aerobic exercise program (OnTrack)
Number of subjects: 63
Study 29124329 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 63
Study 27031376 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral CT with 350 mgI kg(-1) contrast injection
Number of subjects: 50
Study 27031376 — intervention group
Group type: COMPARATOR
Intervention: Standard 120 kVp with 500 mgI kg(-1) contrast
Number of subjects: 50
Study 25910889 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy (L group)
Number of subjects: 84
Study 25910889 — intervention group
Group type: COMPARATOR
Intervention: Control (C group)
Number of subjects: 84
Study 23306077 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally modified DASH intervention (2 individual and 9 group sessions)
Number of subjects: 25
Study 23306077 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 individual session and printed DASH educational materials)
Number of subjects: 25
Study 23306077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 21087825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous arginine (30 g for 5 days)
Number of subjects: 35
Study 21087825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25.2 g of alanine for 5 days)
Number of subjects: 35
Study 18503398 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 5.75 mg once/day (uniform dosage)
Number of subjects: 20
Study 18503398 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 7.5 mg/day on Mondays and Fridays and 5 mg/day on each of the remaining days (nonuniform dosage)
Number of subjects: 20
Study 18503398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both uniform and nonuniform regimens
Number of subjects: 20
Study 16464923 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate and empathetic movie portrayal of schizophrenia
Number of subjects: 165
Study 16464923 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational trailer following the movie
Number of subjects: 165
Study 16464923 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment and educational value of the movie
Number of subjects: 165
Study 16464923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 165
Study 16464923 — intervention group
Group type: EXPERIMENTAL
Intervention: Group who watched a trailer prior to the movie
Number of subjects: 165
Study 12905468 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg)
Number of subjects: 24
Study 12905468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10699472 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to maintain normal pattern of hair washing (group 2)
Number of subjects: 109
Study 10699472 — intervention group
Group type: COMPARATOR
Intervention: Advice not to wash hair during treatment (group 1)
Number of subjects: 109
Study 9336364 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg/m2 IDEC-C2B8
Number of subjects: 20
Study 9336364 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/m2 IDEC-C2B8
Number of subjects: 20
Study 9336364 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/m2 IDEC-C2B8
Number of subjects: 20
Study 8186669 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatments for marijuana dependence
Number of subjects: 167
Study 3533670 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, t.d.)
Number of subjects: 21
Study 29143161 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment (CA)
Number of subjects: 44
Study 29143161 — intervention group
Group type: EXPERIMENTAL
Intervention: CA + BNP
Number of subjects: 44
Study 29143161 — intervention group
Group type: EXPERIMENTAL
Intervention: CA + ECHO
Number of subjects: 44
Study 29143161 — intervention group
Group type: EXPERIMENTAL
Intervention: CA + ECHO + BNP
Number of subjects: 44
Study 28058262 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 (10 cm H2O)
Number of subjects: 49
Study 28058262 — intervention group
Group type: COMPARATOR
Intervention: PEEP 0 (no positive end-expiratory pressure)
Number of subjects: 49
Study 24531025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 33
Study 24531025 — intervention group
Group type: COMPARATOR
Intervention: Macular laser therapy
Number of subjects: 33
Study 22509690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone
Number of subjects: 54
Study 22509690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone
Number of subjects: 54
Study 22509690 — intervention group
Group type: COMPARATOR
Intervention: No prednisone
Number of subjects: 54
Study 21033120 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic red light therapy, once a day, 30 minutes until wounds recovered.
Number of subjects: 138
Study 21033120 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (Control group)
Number of subjects: 138
Study 21033120 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic red light therapy
Number of subjects: 138
Study 18689807 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 203
Study 18689807 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 203
Study 16476542 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min OLV (Group B)
Number of subjects: 132
Study 16476542 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 min OLV (Group C)
Number of subjects: 132
Study 16476542 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 min OLV (Group D)
Number of subjects: 132
Study 16476542 — intervention group
Group type: COMPARATOR
Intervention: No OLV (Group A)
Number of subjects: 132
Study 14560187 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc
Number of subjects: 39
Study 14560187 — intervention group
Group type: COMPARATOR
Intervention: Lumbar fusion
Number of subjects: 39
Study 10840304 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard reusable single‐lumen sphincterotome (group A, n = 38)
Number of subjects: 77
Study 10840304 — intervention group
Group type: COMPARATOR
Intervention: Disposable triple‐lumen sphincterotome with a guidewire (group B, n = 39)
Number of subjects: 77
Study 10840304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per patient for reusable sphincterotome
Number of subjects: 77
Study 10840304 — intervention group
Group type: COMPARATOR
Intervention: Cost per patient for disposable sphincterotome
Number of subjects: 77
Study 9124659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent thermodilution cardiac output measurement
Number of subjects: 12
Study 9124659 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution cardiac output measurement
Number of subjects: 12
Study 9124659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent and continuous cardiac output measurements
Number of subjects: 12
Study 7681894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (PDE inhibitor)
Number of subjects: 12
Study 7681894 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN) patches, 10 mg/24 h
Number of subjects: 12
Study 3752480 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5-1.5 Vol%)
Number of subjects: 24
Study 3752480 — intervention group
Group type: COMPARATOR
Intervention: Neurolept analgesia
Number of subjects: 24
Study 3752480 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 31252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 50
Study 31252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers identified by trialists
Number of subjects: 50
Study 31252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals' endorsement of reporting guidelines
Number of subjects: 50
Study 27740475 — intervention group
Group type: EXPERIMENTAL
Intervention: PatchMatch Filter (PMF)
Number of subjects: 0
Study 27740475 — intervention group
Group type: COMPARATOR
Intervention: Single-scale PMF algorithm
Number of subjects: 0
Study 26420590 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (1 g/d)
Number of subjects: 100
Study 23743397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP), 1,000 mg
Number of subjects: 16
Study 23743397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21649830 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use hydrogen peroxide bleaching agents (PolaDay 7.5%, PolaDay 9.5%, DayWhite ACP-7.5%, DayWhite ACP 9.5%) and in-office agents (PolaOffice 35%, Opalescence XtraBoost 38%) applied for 30 minutes/day for 21 days or in one session a week for 3 weeks.
Number of subjects: 10
Study 21649830 — intervention group
Group type: EXPERIMENTAL
Intervention: DayWhite ACP-7.5%
Number of subjects: 10
Study 20001836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ping On ointment
Number of subjects: 55
Study 20001836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16491462 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal drainage
Number of subjects: 120
Study 16491462 — intervention group
Group type: COMPARATOR
Intervention: No abdominal drainage
Number of subjects: 120
Study 15536462 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (300 mg three times daily)
Number of subjects: 16
Study 15536462 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50 mg three times daily)
Number of subjects: 16
Study 11699402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (CPO) 2 g x 2/day
Number of subjects: 208
Study 11699402 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PT) 4 g x 3/day
Number of subjects: 208
Study 11699402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (CPO)
Number of subjects: 208
Study 11699402 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PT)
Number of subjects: 208
Study 11699402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (CPO) and Piperacillin-tazobactam (PT)
Number of subjects: 208
Study 9232213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) 50 micrograms
Number of subjects: 14
Study 9232213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8501490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation (BMT)
Number of subjects: 161
Study 8501490 — intervention group
Group type: COMPARATOR
Intervention: Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 161
Study 8501490 — intervention group
Group type: COMPARATOR
Intervention: Sequential Postremission Chemotherapy (SPC)
Number of subjects: 161
Study 8501490 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized (NR) patients
Number of subjects: 161
Study 3552835 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 0
Study 3552835 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 31328929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 265
Study 31328929 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD-focused individual psychotherapy
Number of subjects: 265
Study 31328929 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD-focused group psychotherapy
Number of subjects: 265
Study 29450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 350
Study 29450870 — intervention group
Group type: COMPARATOR
Intervention: Medication group (propranolol, amitriptyline, flunarizine, topiramate)
Number of subjects: 350
Study 26331608 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal or poststimulated 17OHP ≥30 nmol/l (group A)
Number of subjects: 40
Study 26331608 — intervention group
Group type: COMPARATOR
Intervention: Poststimulated 17OHP <30 nmol/l (group B)
Number of subjects: 40
Study 25397800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7-mm machined-collar implants
Number of subjects: 25
Study 25397800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-mm machined-collar implants
Number of subjects: 25
Study 22992358 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially tailored mailed intervention based on the Precaution Adoption Process Model, delivered over 3 years to parents and children.
Number of subjects: 677
Study 22992358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 677
Study 20672994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once-daily (QD) with tenofovir DF and emtricitabine
Number of subjects: 664
Study 20672994 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) twice-daily (BID) with tenofovir DF and emtricitabine
Number of subjects: 664
Study 20672994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once-daily (QD)
Number of subjects: 664
Study 20672994 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) twice-daily (BID)
Number of subjects: 664
Study 20672994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) QD
Number of subjects: 664
Study 20672994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) QD and BID
Number of subjects: 664
Study 18833864 — intervention group
Group type: EXPERIMENTAL
Intervention: Finished ion-releasing resin composite at pH 5.0 and 5.5
Number of subjects: 0
Study 18833864 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfinished ion-releasing resin composite at pH 5.5
Number of subjects: 0
Study 18833864 — intervention group
Group type: EXPERIMENTAL
Intervention: Finished ion-releasing resin composite
Number of subjects: 0
Study 18833864 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfinished ion-releasing resin composite
Number of subjects: 0
Study 16011391 — intervention group
Group type: EXPERIMENTAL
Intervention: Working alliance
Number of subjects: 600
Study 16011391 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction
Number of subjects: 600
Study 12477673 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure (n = 135)
Number of subjects: 410
Study 12477673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure on bilateral non-acupressure points (n = 139)
Number of subjects: 410
Study 12477673 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n = 136)
Number of subjects: 410
Study 12477673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cases (P6 acupressure)
Number of subjects: 410
Study 12477673 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery group (P6 acupressure)
Number of subjects: 410
Study 10715372 — intervention group
Group type: COMPARATOR
Intervention: Acidform with 0% N‐9
Number of subjects: 18
Study 10715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform with 2.5% N‐9
Number of subjects: 18
Study 10715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform with 5% N‐9
Number of subjects: 18
Study 7718383 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 40
Study 7718383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 40
Study 7718383 — intervention group
Group type: COMPARATOR
Intervention: Control (non-cannulated upper limb)
Number of subjects: 40
Study 1791565 — intervention group
Group type: COMPARATOR
Intervention: Removable Partial Denture (RPD)
Number of subjects: 228
Study 1791565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPD)
Number of subjects: 228
Study 7234688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate aerosol exposure at a nominal concentration of 75 microgram/m3 (20 microgram iron/m3) for 2 hours
Number of subjects: 38
Study 7234688 — intervention group
Group type: COMPARATOR
Intervention: Clean air (sham) exposure for 2 hours
Number of subjects: 38
Study 30004141 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulations limiting exposure to unwanted drones; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 30004141 — intervention group
Group type: COMPARATOR
Intervention: Regulations hampering drones used for public safety; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 30004141 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulations protecting personal privacy; specific details on dosage and duration not applicable.
Number of subjects: 0